Quick answer
BPC-157 (15-residue synthetic peptide, about 1,419 Da) and TB-500 (thymosin beta-4-derived) are mechanistically distinct and best treated as two separate variables, not alternatives.
- Origin: gastric-derived sequence vs. thymosin beta-4 derivative
- Mechanism: angiogenic/migration signaling vs. actin regulation
- Design: use single-compound arms plus a combined arm
- Products: BPC-157, TB-500 and the paired blend; batch records on the COA page
- Research use: For laboratory research use only; not for human consumption.
For laboratory research use only; not for human consumption.
BPC-157 and TB-500 are the two compounds most often paired in tissue-response research, and they are also often confused. They are not alike. They have different origins, different structures and different mechanistic starting points, and they happen to be studied for overlapping endpoints such as cell migration, angiogenesis and wound-model repair. This comparison sets out what is firmly known about each, what is not, and how to think about choosing between them or studying them together. Each compound has its own guide: BPC-157 research overview and TB-500 research overview.
Origin and structure
- BPC-157 ("body protection compound") is a synthetic pentadecapeptide, 15 amino acids, with a molecular mass of about 1,419 Da. It is derived from a sequence reported in human gastric juice and is unrelated to any growth-factor or cytoskeletal protein family.
- TB-500 is a synthetic peptide derived from thymosin beta-4 (Tβ4), a naturally occurring 43-residue, roughly 4.9 kDa actin-sequestering protein expressed widely across tissues.
The two do not share a parent molecule, a discovery history or a primary mechanism. One is a short synthetic fragment modeled on a stomach-protein sequence; the other is based on a cytoskeletal regulatory protein found throughout the body. Their pairing is a matter of complementary biology and research convenience, not structural similarity.
A naming caution applies to TB-500. The label is used loosely: some sources use it for the full-length Tβ4 sequence and others for a shorter fragment containing the actin-binding region. The sequence and formula on the TB-500 product page (an N-acetylated sequence beginning Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln, with formula C212H350N56O78S) should be compared with the mass reported on the lot COA, because TB-500 mass depends on exactly which sequence a supplier means. Confirming identity by mass is covered in HPLC vs. mass spectrometry.
Mechanistic contrast
BPC-157 is studied largely for cytoprotective and pro-migratory signaling, with the deepest body of preclinical work in gastrointestinal and musculoskeletal injury models. Proposed threads include VEGF/VEGFR2 angiogenic signaling, FAK-paxillin-linked cell migration and nitric-oxide pathway interactions, but a single binding target has not been established, and nearly all of the evidence comes from one network of laboratories using rodent models. Independent replication is limited, and that should temper any strong conclusion.
Tβ4, the parent of TB-500, is better characterized at the molecular level. It binds monomeric G-actin and regulates actin polymerization, and extracellular Tβ4 has been reported to promote endothelial cell migration, angiogenesis and wound closure in animal models (Goldstein et al., 2005; Malinda et al., 1999). Whether a shorter synthetic fragment reproduces the full protein's activities is a separate question that depends on which region the fragment contains, and it should not be assumed.
The practical point: one peptide's published behavior cannot be transferred to the other. Results from BPC-157 in a given assay say little about TB-500 in that assay, and vice versa.
Side-by-side comparison
| Feature | BPC-157 | TB-500 |
|---|---|---|
| Origin | Sequence reported in gastric juice protein | Derived from thymosin beta-4 |
| Length | 15 amino acids (about 1,419 Da) | Fragment or full-length Tβ4 depending on supplier definition |
| Best-known mechanistic thread | Angiogenic and cell-migration signaling; cytoprotection | Actin regulation; cell migration; angiogenesis |
| Strongest research area | Gastrointestinal, tendon and soft-tissue models | Wound-healing, cardiovascular and cell-migration models |
| Evidence base | Largely preclinical, concentrated in few labs | Parent protein studied more widely; fragment data thinner |
| Identity test | Intact mass about 1.42 kDa | Mass must match the sequence the supplier states |
| V8 product | BPC-157 research vial | TB-500 research vial |
Comparators, not competitors
Because their mechanisms do not substitute for each other, BPC-157 and TB-500 are rarely framed as alternatives between which a researcher chooses. They are better framed as two independent variables. Choosing between them for study design really means choosing between two questions: a cytoprotective, migration-and-angiogenesis signaling question (BPC-157), or an actin-cytoskeleton and cell-motility question (TB-500). When a design needs both effects, the standard approach is to include arms for each compound alone and for the pair, so that additive or interacting effects can be separated from either single effect. That design logic is developed in BPC-157 and TB-500 combination research.
Matching the compound to a model system
| Research question | Likely starting point | Why |
|---|---|---|
| Epithelial or gut-barrier models | BPC-157 | Largest published body of work is gastrointestinal |
| Tendon-fibroblast outgrowth and migration | BPC-157 | Reported effects on outgrowth, survival and migration in tendon-cell culture (Chang et al., 2011) |
| Actin dynamics and cell motility | TB-500 | Derived from an actin-regulating protein |
| Endothelial migration and tube formation | Either, or both as separate arms | Both have reported pro-angiogenic activity by different proposed routes |
| Paired signaling and matrix studies | Both, with single-compound controls | Needed to separate additive from interacting effects |
Quality and verification differences
The two materials behave differently on the bench, which affects how they are verified. BPC-157 is a short, cysteine-free, proline-rich 15-mer that is robust and straightforward to verify by HPLC and intact mass. A longer actin-binding peptide such as TB-500 has more residues that can go wrong in synthesis (deletions, truncations, methionine oxidation, deamidation), so the chromatogram and mass spectrum deserve closer inspection and the stated sequence should be matched against the observed mass. Both should come with a lot-specific COA; see how to read a COA and understanding HPLC purity. Per-compound testing pages are BPC-157 purity testing and TB-500 purity testing, and the paired product is covered in BPC-157 + TB-500 third-party testing.
Handling both in the lab
Both are supplied as lyophilized powder. V8 specifies storage at 2–8 °C, with −20 °C for long-term storage, protected from heat, moisture and light. Once reconstituted, concentration is mass divided by diluent volume: for example, 10 mg in 2 mL is 5 mg/mL, and the calculator returns the same figure for other combinations. Aliquot to avoid repeated freeze-thaw cycles. For blend products, record the concentration of each component separately. Specific steps are in BPC-157 + TB-500 blend reconstitution.
Single vials or the paired blend
V8 lists each compound on its own, BPC-157 and TB-500 (10 mg), and also the paired BPC-157 + TB-500 blend (10 mg / 10 mg). Single vials suit designs that need compound-specific controls and independent concentration choices; the blend fixes the ratio, which suits designs built around that specific pairing. The COA page organizes batch documentation, and the blend page links to a lot-specific COA. For a wider view of recovery-related compounds, see best research peptides 2026.
Frequently asked questions
Are BPC-157 and TB-500 the same kind of peptide?
No. BPC-157 is a 15-residue synthetic sequence modeled on a gastric protein; TB-500 is derived from thymosin beta-4, an actin-binding protein. They have separate origins and mechanisms.
Which one has more published research?
Thymosin beta-4, TB-500's parent, has been studied more broadly, while BPC-157 has a large preclinical literature concentrated in a small number of laboratories. Neither is an approved compound, and independent replication varies by endpoint.
Can I predict TB-500 behavior from BPC-157 data?
No. Their mechanisms differ, so results from one do not transfer to the other. Each needs its own controls in an assay.
Why do two TB-500 products sometimes have different masses?
The name is used for different sequences, either full-length thymosin beta-4 or a fragment. Compare the mass on the lot COA with the sequence the supplier states.
Should I study them separately or together?
Include single-compound arms alongside the combined arm. Without them, you cannot tell whether an effect is additive, interacting or due to one compound.
What mass does BPC-157 show on mass spectrometry?
About 1,419 Da for the intact 15-residue peptide. Use that as the reference for identity testing.
Does V8 sell TB-500 on its own?
Yes. The TB-500 product page lists a 10 mg vial with ≥98% HPLC purity. The paired blend is the BPC-157 + TB-500 research blend.
How are stock concentrations calculated?
Peptide mass in the vial divided by diluent volume, in mg/mL. For a blend, calculate each component separately. See the calculator.
Research Use Only. For laboratory research use only; not for human consumption. Supplied strictly for laboratory research and development, not for human or veterinary use, and not for any diagnostic or clinical purpose. This article is research education, not usage guidance.
References
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429.
- Malinda KM, Sidhu GS, Mani H, et al. Thymosin β4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368.
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780.
- BPC-157 research overview
- TB-500 research overview
- BPC-157 and TB-500 combination research